A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

• Drug: WM-S1-030

Inclusion Criteria

1. Aged ≥18 years.
2. Able and willing to sign the informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. form (ICF).
3. Have at least 1 evaluable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
4. Have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor which has progressed after treatment with standard therapies and for which no effective standard therapy is available or patient has refused, has a contraindication, or is intolerant to standard therapies.
5. Have Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status ≤2.
6. Must have archived frozen tissuea group of cells that work together to perform a function available (collected within 3 months before screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening) or consent to a pre-treatment biopsyremoval of a section of tissue to analyse for cancer cells.
7. Must be willing to consent to up to 2 on-treatment biopsies.
8. Have a life expectancy of at least 12 weeks.
9. Have adequate hematological functions and bloodthe red bodily fluid that transports oxygen and other nutrients around the body coagulation.
10. Have adequate hepatic function at screening.
11. Have adequate renal function at screening.
12. QT interval corrected for heart rate using Fridericia’s method ≤470 msec.
13. Agree to abide by contraception requirements.
14. Body massa growth of cells that come together to make a lump, may or may not be cancer index between 18 and 35 kg/m2 (exclusive)